IQVIA (NYSE:IQV) Reaches New 52-Week High – Still a Buy?

IQVIA Holdings Inc. (NYSE:IQV) hit a new 52-week high on Tuesday . The company traded as high as $272.00 and last traded at $270.9470, with a volume of 425985 shares. The stock had previously closed at $265.67.

Analyst Ratings Changes

A number of analysts recently commented on the company. Weiss Ratings raised IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, July 15th. Morgan Stanley reissued an “equal weight” rating and issued a $200.00 price objective (down from $225.00) on shares of IQVIA in a research report on Wednesday, June 17th. HSBC restated a “buy” rating and issued a $240.00 price objective on shares of IQVIA in a research note on Monday, July 6th. Barclays reiterated an “overweight” rating on shares of IQVIA in a research note on Tuesday, July 28th. Finally, Deutsche Bank Aktiengesellschaft set a $240.00 price target on shares of IQVIA in a report on Thursday, July 9th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $243.62.

IQVIA Stock Up 1.7%

The firm has a market capitalization of $44.46 billion, a PE ratio of 33.55, a P/E/G ratio of 2.24 and a beta of 1.18. The stock has a 50-day simple moving average of $237.75 and a 200-day simple moving average of $196.87. The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 2.18.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, beating analysts’ consensus estimates of $3.03 by $0.12. The firm had revenue of $4.37 billion for the quarter, compared to analysts’ expectations of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The business’s revenue for the quarter was up 8.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Analysts forecast that IQVIA Holdings Inc. will post 11.57 EPS for the current year.

Insider Buying and Selling at IQVIA

In other news, insider James G. Berkshire sold 2,668 shares of the business’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $261.33, for a total value of $697,228.44. Following the sale, the insider owned 10,890 shares of the company’s stock, valued at $2,845,883.70. The trade was a 19.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Keriann Cherofsky sold 558 shares of the firm’s stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total transaction of $136,827.18. Following the completion of the transaction, the insider directly owned 2,989 shares of the company’s stock, valued at approximately $732,932.69. This trade represents a 15.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 15,581 shares of company stock valued at $3,796,021. Insiders own 1.70% of the company’s stock.

Institutional Investors Weigh In On IQVIA

A number of hedge funds and other institutional investors have recently bought and sold shares of IQV. International Assets Investment Management LLC bought a new stake in shares of IQVIA during the 4th quarter valued at $27,000. Compass Financial Management LLC bought a new position in IQVIA in the 2nd quarter worth about $27,000. Financial Freedom LLC purchased a new position in IQVIA during the 1st quarter valued at about $25,000. Ascentis Independent Advisors bought a new stake in shares of IQVIA during the first quarter valued at about $25,000. Finally, Elevation Wealth Partners LLC increased its position in shares of IQVIA by 218.8% during the second quarter. Elevation Wealth Partners LLC now owns 153 shares of the medical research company’s stock valued at $30,000 after buying an additional 105 shares during the period. Institutional investors own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc is a global provider of advanced analytics, technology solutions and contract research services for the life sciences industry. The company supports pharmaceutical, biotechnology and medical device companies throughout the product life cycle, from research and clinical development through commercialization and post-market activities.

Its offerings include clinical trial management, site and patient services, real-world evidence, healthcare data, regulatory and safety services, commercial analytics, consulting, and technology platforms.